|
Drug Quality Still Lacking; FDA Considering QbD Incentives
BALTIMORE — Despite recurring pharma quality problems, drugmakers are still inclined to meet minimum manufacturing standards set by regulators, rather than make quality central to their business model.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives